New data from two clinical studies indicate high-risk and recurrent prostate cancers can be effectively treated in 5 days using the accuray cyberknife® system

Data also underscores potential benefits of cyberknife system sub-millimeter accuracy in preserving quality of life after treatment for prostate cancer madison, wis. , march 26, 2024 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that new data presented at the 2024 radiosurgery society meeting in chicago, illinois support the use of the cyberknife ® system in the treatment of high-risk and recurrent prostate cancer.
ARAY Ratings Summary
ARAY Quant Ranking